ATLANTA, November 16, 2010 - NeurOp Corporation today announced that Harold Shlevin, Ph.D., has joined its board of directors. Shlevin is a bioscience-industry executive with more than 30 years’ experience in medical devices, pharmaceuticals, diagnostics and vaccines. He currently leads Georgia Tech’s Advanced Technology Development Center (ATDC) as general manager of bioscience commercialization efforts. Shlevin also serves on the boards of Cardiome Pharma Corporation, Georgia Bio and several non-profit organizations.
“Harold has a particularly strong background in business development, strategic planning and licensing,” said James McNamara, M.D., NeurOp’s chairman. “He brings additional depth to our board as NeurOp prepares to advance its first drug candidate into clinical trials for depression and expand its drug discovery program for ischemia.”
“Developing and marketing treatments for central nervous system diseases has long been an area of keen interest for me,” commented Shlevin. “I am privileged to join the NeurOp board and look forward to applying my years of R&D and management experience to help direct their corporate growth and development of new medicines.”
At ATDC, Shlevin is responsible for evaluating and guiding new and emerging bioscience enterprises. His past industry experience includes CEO of Solvay Pharmaceuticals, Inc. and leadership roles at G.D. Searle and Co., Ciba-Geigy Corporation and Altea Therapeutics; he was also a founder of Ciba Vision Ophthalmics and Tikvah Therapeutics. He earned a bachelor’s degree from Boston University and a master’s and doctorate in physiology from the University of Rochester Medical School. He holds a post-doctoral certificate in pharmacology and physiology from the Mayo Graduate School of Medicine where he was an assistant professor.
NeurOp, Inc., based in Atlanta, Georgia, is a biopharmaceutical company developing innovative medicines for central nervous system disorders including depression, neuropathic pain and ischemia. Its most advanced compounds modulate a well-validated target, the NMDA receptor, in a manner designed to enhance therapeutic benefit while alleviating side effects associated with previous generations of this drug class. A research collaboration with Bristol-Myers Squibb Company (NYSE: BMY) currently funds and supports the development of NeurOp’s proprietary small molecules for the treatment of depression and neuropathic pain. For more information, please visit www.neuropinc.com.
Barney Koszalka, CEO